DOCSLIB.ORG

Opioid-Induced Constipation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opioid-Induced Constipation Veterans’MATES www.veteransmates.net.au Opioid-induced constipation Inside 1 How opioids cause constipation – a preventable problem 1 Impact of opioid-induced constipation One of the most common adverse effects of chronic opioid 2 Managing opioid-induced constipation 3 Prevention and treatment of opioid- 1-4 therapy is constipation. Up to 95% of patients prescribed an induced constipation 4-6 opioid report constipation as a side effect, which can occur 4 Other factors affecting constipation soon after taking the first dose.6 4 Ongoing patient management Older adults tend to be at higher risk of constipation because of immobility, poor diet, poor fluid intake and concurrent use of constipating medicines.7 Older adults suffering Key points from chronic pain are likely to be less active, treated with opioid analgesics and therefore, are at considerable risk of developing constipation. Constipation is a debilitating adverse effect of opioid To prevent opioid-induced constipation, Australian guidelines recommend prescribing analgesics. suitable laxatives concurrently with opioid analgesics.1,7,8 An analysis of the DVA When initiating an opioid dataset found that of the 42,000 members in the veteran community dispensed an analgesic, consider a 9 opioid analgesic, over 70% were not concurrently dispensed a laxative. combined stimulant laxative Other medicines, particularly those that are highly anticholinergic, can also cause with a stool softener. constipation, which may further compound the problem.10 Osmotic laxatives may be This therapeutic brief outlines how to prevent and treat opioid-induced constipation, appropriate for patients in palliative care or for those with including the most appropriate laxatives to use, and highlights commonly used non-responsive constipation. medicines that may also contribute to constipation. Review use of bulking agents. Review other medicines that How opioids cause Impact of opioid- may further contribute to constipation induced constipation constipation. Opioids cause constipation by Opioid-induced constipation can be so Opioid-induced constipation has an impact binding to specific receptors in the intolerable that it causes significant on quality of life that is comparable to gastrointestinal tract and central nervous social and psychological trauma for other common chronic conditions.6,12,14 system, resulting in reduced bowel patients. It has been reported to be Some patients would rather endure motility through direct and indirect the most bothersome side effect of chronic pain than suffer from the severe (anticholinergic) mechanisms. The opioid analgesics.5 Unmanaged chronic constipation that can arise with long- delayed colonic transit time discourages constipation may cause rectal pain term opioid therapy.3 One study found defecation, and causes excessive water and bleeding, abdominal pain and that approximately one-third of patients and electrolyte re-absorption from distension, urinary incontinence, faecal missed, decreased or stopped using faeces, which further dehydrates stool.4,5 impaction, rectal tearing, and, in very opioids in order to make it easier to have a bowel motion; the majority (86%) of these Most patients develop some degree of severe cases, bowel obstruction and 6,7,12 patients experienced increased pain as a constipation after opioid initiation. Even colonic perforation. In a study of result, which reduced their quality of life.5,6 though tolerance develops to some patients who had dementia and were Reducing the opioid dose is not considered opioid adverse effects, constipation living in a nursing home, physical useful, as analgesia may be compromised often persists unless remedial measures aggression was shown to be associated 13 and constipation may not resolve.3,4 are taken.2,4,5,11 with constipation. Veterans’ Medicines Advice and Therapeutics Education Services Therapeutic Brief 27 – Opioid-induced constipation - a preventable problem. June 2011. Veterans’MATES Managing opioid-induced constipation The aim is to prevent opioid-induced In established cases of constipation, a of laxative may also be influenced constipation. If a patient develops this rectal examination is usually necessary as by patients’ preferences, routes of adverse effect, the goal is to return it can reveal the presence of soft or dry administration, side effects and the bowel function to an acceptable level for faeces, or faecal impaction, which may required onset of action. Osmotic that patient. influence the laxative choice. Sometimes, laxatives may be appropriate for patients a plain abdominal x-ray is also performed, in palliative care, those with malignant Assessment although there is a poor correlation neoplasia or for those with non- There is no objective definition of between symptoms and the extent of responsive constipation (see table 1). constipation because of the great 7,15 faecal loading shown on x-ray. Generally, bulking agents are not individual variation in normal bowel habits, recommended for patients with opioid- and because patients and healthcare Pharmacological management induced constipation as they increase professionals can vary significantly in Before starting opioid therapy, discuss the risk of bowel obstruction, especially their definition of constipation.4, 7,10 In the associated risk of constipation and if the patient has poor fluid intake or broad terms, constipation is described as the possible need for taking laxatives is immobile.7 infrequent defecation (generally fewer than with the patient.3,4 These recommendations also 3 times per week), often with straining and In conjunction with lifestyle measures 1 apply to palliative care patients taking passage of hard, uncomfortable stools. (page 4), consider a combined stimulant opioid analgesics. laxative with a stool softener when initiating opioids.1,7,8 The use and choice Table 1 includes a list of laxatives by class that are appropriate for managing opioid-induced constipation. Table 1: Laxatives used for opioid-induced constipation1,7,8,15,16 Oral laxatives Class Generic name (Brand name) Administration & Safety considerations Combined Docusate sodium + senna stimulant laxative (e.g. Coloxyl with Senna®) RPBS with stool softener Can be used long-term in patients taking opioids. There is no convincing evidence to suggest that chronic Senna standardised (e.g. Senokot®) RPBS use of stimulant laxatives causes cathartic colon or Stimulant laxatives colonic injury. Bisacodyl (e.g. Bisalax®, Dulcolax®) PBS Restricted a,b,c Often combined with a stimulant laxative for opioid- Stool softeners Docusate sodium (e.g. Coloxyl®) RPBS induced constipation. There is limited evidence to show effectiveness of stool softeners when used alone. Macrogol (polyethylene glycol) laxative Fluid and electrolyte disturbances may occur – use with (e.g. Movicol®, Osmolax®) PBS Restricted b,c,d caution in cardiovascular disease (e.g. heart failure) and renal impairment (less of a risk with macrogol laxatives). Saline laxatives containing magnesium Laxatives containing sodium phosphate are not (e.g. Epsom Salts) Not PBS listed recommended for the elderly (e.g. Fleet®). Osmotic laxatives Lactulose syrup (e.g. Actilax®, Duphalac®) Contraindicated in intestinal obstruction. PBS Restricted b,c Flatulence is a common adverse effect. Avoid lactulose if fluid intake is poor. Sorbitol liquid (e.g. Sorbilax®) Not PBS listed Lactulose contains galactose and lactose. Rectal laxatives Sodium citrate + sodium lauryl sulfoacetate + sorbitol enemas – also known as saline laxatives (e.g. Rectal laxatives may be used for faecal impaction or if Osmotic laxatives Microlax®) RPBS there is insufficient response to oral laxatives. Avoid embedding suppositories in faecal matter, as it Glycerol suppositories RPBS delays the laxative effect. ® Bisacodyl enemas (e.g. Bisalax ) and suppositories ® Stimulant laxatives Avoid sodium phosphate enemas (e.g. Fleet ). (e.g. Bisalax®, Dulcolax®) PBS Restricted a,b,c a Patient in residential aged care facility. b Palliative care. c Malignant neoplasia. d Non-responsive constipation or faecal impaction. See PBS Schedule for complete list of restricted benefits. Veterans’ Medicines Advice and Therapeutics Education Services Therapeutic Brief 27 – Opioid-induced constipation - a preventable problem. June 2011. Veterans’MATES Prevention and treatment of opioid-induced constipation*1,7,8,15 Scenario Recommendation Considerations Prevention Opioid initiation Consider the use of a combined stimulant laxative Since opioids reduce peristalsis, with a stool softener, such as docusate sodium causing hard faeces to form, the most + senna (e.g. Coloxyl with Senna®). An osmotic useful laxatives are those that increase laxative may also be appropriate, such as macrogol peristalsis and soften the stool. (e.g. Movicol®, Osmolax®) or lactulose Bulking agents are not recommended. (e.g. Actilax®). Treatment Established If not initiated with opioid therapy, consider use of constipation a combined stimulant laxative with a stool softener – such as docusate sodium + senna (e.g. Coloxyl with Senna®). If initial management is ineffective: • for hard faeces consider adding an oral osmotic laxative, such as macrogol (e.g. Movicol®, Osmolax®) or lactulose (e.g. Actilax®). • for soft faeces consider adding another oral stimulating agent, such as bisacodyl (e.g. Bisalax®). Non-responsive If the regular laxative regimen is unsuccessful, For palliative care patients, (refractory) constipation consider the following management options: methylnaltrexone
Load more

Recommended publications
  • Instruction Sheet: Constipation
    University of North Carolina Wilmington Abrons Student Health Center INSTRUCTION SHEET: CONSTIPATION The Student Health Provider has treated you for constipation. Constipation consists of a change from your usual pattern, with stools becoming less frequent and more difficult to pass. There is no set number of bowel movements a person should have each day or week. People vary widely in frequency of bowel movements, from three times a day to three times a week. Most everyone experiences constipation sometime in his/her life. Certain medicines, such as prescription pain pills, calcium antacids, calcium supplements, antihistamines, diet pills, calcium channel blockers, and diuretics (fluid pills) can cause constipation. Other factors which increase constipation include age, pregnancy, chronic laxative abuse, and a diet low in fiber. Americans, in general, consume a low fiber diet. Fiber acts as a natural laxative: Fiber draws water into the stool and increases the bulk of stools, resulting in softer stools and more rapid movement of stools through the intestine. Fiber in the diet not only minimizes constipation; fiber may prevent diverticulitis, hemorrhoids, intestinal polyps, and even cancer of the bowel. A high fiber diet is also helpful in weight control/reduction. MEASURES WHICH YOU SHOULD TAKE TO HELP TREAT AND PREVENT CONSTIPATION: 1. Drink plenty of fluids every day. Four to six glasses of water or other non-alcoholic beverage help keep stools soft. 2. Exercise daily. Even mild exercise like walking improves bowel function. 3. Consume a diet high in fiber. Fruits, vegetables, whole wheat bread, oatmeal, and bran cereal are all high in fiber.
    [Show full text]
  • Bronson Healthcare Midwest Epic Review of Systems 10.3
    Bronson HealthCare Midwest Epic Review of Systems 10.3 Constitution Endocrine Activity Change Y N Cold intolerance Y N Appetite Change Y N Heat intolerance Y N Chills Y N Polydipsia Y N Diaphoresis Y N Polyuria Y N Fatigue Y N GU Fever Y N Difficulty urinating Y N Unexpctd wt chnge Y N Dyspareunia Y N HENT Dysuria Y N Facial Swelling Y N Enuresis Y N Neck pain Y N Flank pain Y N Neck stiffness Y N Frequency Y N Ear Discharge Y N Genital Sore Y N Hearing loss Y N Hematuria Y N Ear pain Y N Menstrual problem Y N Tinnitus Y N Pelvic pain Y N Nosebleeds Y N Urgency Y N Congestion Y N Urine decreased Y N Rhinorrhea Y N Vaginal bleeding Y N Postnasal drip Y N Vaginal discharge Y N Sneezing Y N Vaginal pain Y N Sinus Pressure Y N Musc Dental problem Y N Arthralgias Y N Drooling Y N Back pain Y N Mouth sores Y N Gait problem Y N Sore throat Y N Joint swelling Y N Trouble swallowing Y N Myalgias Y N Voice Change Y N Skin Eyes Color change Y N Eye Discharge Y N Pallor Y N Eye itching Y N Rash Y N Eye pain Y N Wound Y N Last Name: ___________________________________ First Name: ______________________________________ Date of Birth: _____________________________ Today’s Date: __________________________________________ Bronson HealthCare Midwest Epic Review of Systems 10.3 Eye redness Y N Allergy/Immuno Photophobia Y N Env allergies Y N Visual disturbance Y N Food Allergies Y N Respiratory Immunocompromised Y N Apnea Y N Neurological Chest tightness Y N Dizziness Y N Choking Y N Facial asymmetry Y N Cough Y N Headaches Y N Shortness of breath Y N Light-headedness
    [Show full text]
  • Final Stakeholder List PDF 190 KB
    Appendix C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Naldemedine for treating opioid-induced constipation [ID1189] Matrix of consultees and commentators Consultees Commentators (no right to submit or appeal) Company General • Shionogi (naldemedine) • All Wales Therapeutics and Toxicology Centre Patient/carer groups • Allied Health Professionals Federation • Action on Pain • Board of Community Health Councils in • Black Health Agency Wales • Bladder and Bowel Community • British National Formulary • Bladder and Bowel UK • Care Quality Commission • Cancer Black Care • Department of Health, Social Services • Cancer Equality and Public Safety for Northern Ireland • Guts UK • Healthcare Improvement Scotland • HAWC • Medicines and Healthcare products • Helen Rollason Cancer Charity Regulatory Agency • IBS Network • National Association of Primary Care • Independent Cancer Patients Voice • National Pharmacy Association • Macmillan Cancer Support • NHS Alliance • Maggie’s Centres • NHS Confederation • Marie Curie • Scottish Medicines Consortium • Muslim Council of Britain • Scottish Society of Gastroenterology • Pain Concern • Welsh Health Specialised Services • Pain Relief Foundation Committee • Pain UK • South Asian Health Foundation Possible comparator companies • Specialised Healthcare Alliance • Actavis UK (glycerol suppositories, • Tenovus Cancer Care bisacodyl, lactulose, senna) • Wellbeing of Women • Cardinal Health Martindale Products • Women’s Health Concern (glycerol suppositories) • Concordia International
    [Show full text]
  • Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease
    J Am Soc Nephrol 9: 1924-1930. 1998 Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease CHRISTINE GRUY-KAPRAL, MICHAEL EMMETT, CAROL A. SANTA ANA, JACK L. PORTER, JOHN S. FORDTRAN, and KENNETH D. FINE Departnzent of Internal Medicine, Baylor Universirs’ Medical Center, Dallas, Texas. Abstract. Hyperkalemia in patients with renal failure is fre- slightly (0.4 mEqIL) during the I 2-h experiment. This rise was quently treated with a cation exchange resin (sodium polysty- apparently abrogated by some of the regimens that included rene sulfonate, hereafter referred to as resin) in combination resin; this may have been due in part to extracellular volume with a cathartic, but the effect of such therapy on serum expansion caused by absorption of sodium released from resin. potassium concentration has not been established. This study Phenolphthalein regimens were associated with a slight rise in evaluates the effect of four single-dose resin-cathartic regimens serum potassium concentrations (similar to placebo); this may and placebo on 5 different test days in six patients with chronic have been due to extracellular volume contraction produced by renal failure. Dietary intake was controlled. Fecal potassium high volume and sodium-rich diarrhea and acidosis secondary output and serum potassium concentration were measured for to bicarbonate losses. None of the regimens reduced serum 12 h. Phenobphthalein alone caused an average fecal potassium potassium concentrations, compared with baseline levels. Be- output of 54 mEq. The addition of resin caused an increase in cause single-dose resin-cathartic therapy produces no or only insoluble potassium output but a decrease in soluble potassium trivial reductions in serum potassium concentration, and be- output; therefore, there was no significant effect of resin on cause this therapy is unpleasant and occasionally is associated total potassium output.
    [Show full text]
  • Medicines That Affect Fluid Balance in the Body
    the bulk of stools by getting them to retain liquid, which encourages the Medicines that affect fluid bowels to push them out. balance in the body Osmotic laxatives e.g. Lactulose, Macrogol - these soften stools by increasing the amount of water released into the bowels, making them easier to pass. Older people are at higher risk of dehydration due to body changes in the ageing process. The risk of dehydration can be increased further when Stimulant laxatives e.g. Senna, Bisacodyl - these stimulate the bowels elderly patients are prescribed medicines for chronic conditions due to old speeding up bowel movements and so less water is absorbed from the age. stool as it passes through the bowels. Some medicines can affect fluid balance in the body and this may result in more water being lost through the kidneys as urine. Stool softener laxatives e.g. Docusate - These can cause more water to The medicines that can increase risk of dehydration are be reabsorbed from the bowel, making the stools softer. listed below. ANTACIDS Antacids are also known to cause dehydration because of the moisture DIURETICS they require when being absorbed by your body. Drinking plenty of water Diuretics are sometimes called 'water tablets' because they can cause you can reduce the dry mouth, stomach cramps and dry skin that is sometimes to pass more urine than usual. They work on the kidneys by increasing the associated with antacids. amount of salt and water that comes out through the urine. Diuretics are often prescribed for heart failure patients and sometimes for patients with The major side effect of antacids containing magnesium is diarrhoea and high blood pressure.
    [Show full text]
  • Health History – Surgical Associates, Pc 575 S
    HEALTH HISTORY – SURGICAL ASSOCIATES, PC 575 S. 70th Street, Suite 310 Lincoln, NE 68510 Date:_______________________________________ Name _____________________________________________________________ Age _______ Gender: M / F Family Doctor:____________________________________ Sent to our office by:____________________________________ Reason for seeing doctor: Problem/Symptoms: ____________________________________________________________ _______________________________________________________________________________________________________________ Currently Treated/Chronic Medical Problems: Acid Reflux Anxiety Asthma (type_________) Afib BPH (Benign Prostatic Hyperplasia) Coronary Artery Disease Cancer (type_________) CHF (Congestive Heart Failure) Chronic Migraines COPD Crohn’s CVA (Cerebral Infarction) Depression Diverticulitis Emphysema Factor 5 Leiden Mutation GERD Hepatitis Hypertension/High Blood Pressure High Cholesterol HIV Hypothyroid IBS (Irritable Bowel Syndrome) Joint Pain (joint_______) Back Pain Malignant Hyperthermia Morbid Obesity Obstructive Sleep Apnea PCOS Pneumonia Psychological Illness Renal Disease Sleep Apnea Type I diabetes Type II diabetes Ulcerative Colitis Urinary Incontinence Weight related injury (specify _____________________) Pregnant (week gestation ______) Other: _____________________________________________________________________________ Prior Surgeries & Approximate Date: (please circle or fill in blanks, dates can be written in below the procedure) Adenoidectomy
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • Supplementary File 1
    Supplementary File Table S1 Checklist for Documentation of Google Trends research. a) Initial list of pain locations and factors related to pain Name Matched as topic related to pain (not disease diagnosis) Head & Neck Headache / Head Pain Yes, „Headache” Eye pain Yes „Eye pain” Nose pain No Ear pain Yes, „Ear pain” Toothache Yes, „Toothache” Tongue pain No Lip pain No Sore Throat Yes, „Sore Throat” Neck pain Yes, „Neck pain” Trunk Chest pain / Heart pain Yes, „Chest pain” Breast pain Yes, „Breast pain” Abdominal pain / Stomache Yes, „Abdominal pain” Epigastric pain Yes, „Epigastric pain” Umbilical pain No Flank pain Yes, „Abdominal pain” Hypogastrium pain No Groin pain Yes, „Groin pain” Back pain Yes, „Back pain” Low back pain / Lumbar pain Yes, „Low back pain” Pelvic region Pelvic pain Yes, „Pelvic pain” Penis pain Yes, „Penile pain” Testicular pain / Pain of balls Yes, „Testicular pain” Rectum pain / Anal pain Yes, „Rectum pain” Limbs Shoulder pain Yes, „Shoulder pain” Clavicle pain No Arm pain No Forearm pain No Wrist pain Yes, „Wrist pain” Hand pain / Palm pain No Thigh pain No Buttock pain No Knee pain Yes, „Knee pain” Calf pain / Calf cramps No Podalgia / Feet pain Yes, „Podalgia” Factors Dysmennorhea / Painful Yes, „Dysmenorrhea” mennorhea Dyspareunia / Sex during Yes, „Dyspareunia” intercourse Odynophagia / Pain during Yes, „Odynophagia” swallowing Pain during breathing No Pain during walking No b) Search details Section/Topic Checklist item Search Variables Access Date 22 July 2019 Time Period From January 2004 to date of the
    [Show full text]
  • 3.2.2 Misuse of Stimulant Laxatives
    Medicines Adverse Reactions Committee Meeting date 10/06/2021 Agenda item 3.2.2 Title Misuse of stimulant laxatives Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Bisacodyl Bisacodyl Laxative (Pharmacy Health) PSM Healthcare Limited trading as API tablet Consumer Brands Dulcolax tablet Sanofi-Aventis New Zealand Limited Dulcolax Suppository Sanofi-Aventis New Zealand Limited *Lax-Suppositories Bisacodyl AFT Pharmaceuticals Limited *Lax-Tab tablet AFT Pharmaceuticals Limited Docusate sodium *Coloxyl tablet Pharmacy Retailing (New Zealand) Limited trading as Healthcare Logistics Docusate sodium + Coloxyl with Senna tablet Pharmacy Retailing (New Zealand) sennosides Limited trading as Healthcare Logistics *Laxsol tablet Pharmacy Retailing (New Zealand) Limited trading as Healthcare Logistics Glycerol *Glycerol Suppositories PSM Healthcare Limited trading as API Consumer Brands Sennosides *Senokot tablet Reckitt Benckiser (New Zealand) Limited Sodium picosulfate Dulcolax SP Drops oral solution Sanofi-Aventis New Zealand Limited PHARMAC funding *Pharmaceutical Schedule Lax-Tab tablets, Lax-Suppositories Bisacodyl, Coloxyl tablets and Glycerol Suppositories are fully-funded only on a prescription. Senokot tablets are part- funded. Previous MARC Misuse of stimulant laxatives has not been discussed previously. meetings International action Following a national safety review published in August 2020, the MHRA in the UK has introduced pack size restrictions, revised recommended ages for use
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Assessment Report on Ricinus Communis L., Oleum Final
    2 February 2016 EMA/HMPC/572973/2014 Committee on Herbal Medicinal Products (HMPC) Assessment report on Ricinus communis L., oleum Final Based on Article 10a of Directive 2001/83/EC as amended (well-established use) Herbal substance(s) (binomial scientific name Ricinus communis L., oleum (castor oil) of the plant, including plant part) Herbal preparation Fatty oil obtained from seeds of Ricinus communis L. by cold expression Pharmaceutical forms Herbal preparation in liquid or solid dosage forms for oral use Rapporteur C. Purdel Peer-reviewer B. Kroes 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Search and assessment methodology ..................................................................... 6 2. Data on medicinal use ........................................................................................................ 6 2.1. Information about products on the market .............................................................
    [Show full text]
  • Chronic Constipation: an Evidence-Based Review
    J Am Board Fam Med: first published as 10.3122/jabfm.2011.04.100272 on 7 July 2011. Downloaded from CLINICAL REVIEW Chronic Constipation: An Evidence-Based Review Lawrence Leung, MBBChir, FRACGP, FRCGP, Taylor Riutta, MD, Jyoti Kotecha, MPA, MRSC, and Walter Rosser MD, MRCGP, FCFP Background: Chronic constipation is a common condition seen in family practice among the elderly and women. There is no consensus regarding its exact definition, and it may be interpreted differently by physicians and patients. Physicians prescribe various treatments, and patients often adopt different over-the-counter remedies. Chronic constipation is either caused by slow colonic transit or pelvic floor dysfunction, and treatment differs accordingly. Methods: To update our knowledge of chronic constipation and its etiology and best-evidence treat- ment, information was synthesized from articles published in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Levels of evidence and recommendations were made according to the Strength of Recommendation taxonomy. Results: The standard advice of increasing dietary fibers, fluids, and exercise for relieving chronic constipation will only benefit patients with true deficiency. Biofeedback works best for constipation caused by pelvic floor dysfunction. Pharmacological agents increase bulk or water content in the bowel lumen or aim to stimulate bowel movements. Novel classes of compounds have emerged for treating chronic constipation, with promising clinical trial data. Finally, the link between senna abuse and colon cancer remains unsupported. Conclusions: Chronic constipation should be managed according to its etiology and guided by the best evidence-based treatment.(J Am Board Fam Med 2011;24:436–451.) copyright. Keywords: Chronic Constipation, Clinical Review, Evidence-Based Medicine, Family Medicine, Gastrointestinal Problems, Systematic Review The word “constipation” has varied meanings for was established in 1991 by Drossman et al, primar- different individuals.
    [Show full text]